News | November 18, 2011

First Patients Implanted with Watchman LAA Occluder in Latin America

November 18, 2011 – Boston Scientific’s Watchman left atrial appendage (LAA) closure device has been implanted in the first patients in Latin America. The device is designed for use in patients in atrial fibrillation who are at risk for stroke and are eligible for long-term oral anticoagulation therapy such as warfarin. Watchman is intended to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. The first patient implants were performed by Bernardo Caicedo, M.D., interventional cardiologist, at Angiografia de Occidente in Cali, Colombia.

Atrial fibrillation, which affects approximately 15 million patients worldwide, is a disorder that disrupts the heart's ability to beat regularly and pump blood efficiently. Patients in atrial fibrillation are at greater risk for stroke due to the formation and migration of clots in the left atrial appendage. Anticoagulants such as warfarin have traditionally been the only therapy for reducing stroke risk in these patients. Watchman is intended to be an alternative to long-term anticoagulation. It is designed to close the LAA, thereby preventing clots within the appendage from being dislodged into the bloodstream.

"I am excited to be part of the first patient implants of the Watchman device in Latin America," said Caicedo. "The percutaneously delivered device promises to offer a safe and effective alternative for atrial fibrillation patients who cannot take long-term oral anticoagulants and have limited options to reduce their stroke risk. It incorporates a pre-loaded device that is both repositionable and retrievable to enhance its ease of use."

Watchman is the most clinically studied product of its kind currently available. In the multi-center, randomized PROTECT AF clinical trial, it proved to be non-inferior to warfarin and demonstrated a 38 percent relative risk reduction for a combined measure of stroke, cardiovascular death and systemic embolism compared to long-term warfarin therapy in 800 patients. The study also showed a 29 percent relative risk reduction in all stroke and a 90 percent relative risk reduction in hemorrhagic stroke compared to warfarin. Nearly 1,800 patients have now been recruited in Wacthman clinical trials with more than 2,700 patient-years of follow-up. Watchman is CE Marked and was commercialized outside the United States in 2009.

Boston Scientific is currently enrolling United States patients in the PREVAIL study, a confirmatory study designed to gain U.S. Food and Drug Administration (FDA) approval. Enrollment is expected to be completed in the first quarter of 2012. In the United States, Watchman is an investigational device, limited by applicable law to investigational use and not available for sale. The device was developed by Atritech, which Boston Scientific acquired in March 2011.

For more information: www.bostonscientific.com

 

Related Content

The Robocath R-One cath lab robotic platform being used in Rouen, France, to guide a cardiac Cath procedure. The system gained European approval in 2019. Robocath is now partnering with Philips France and Rennes University Hospital to develop the robotic system to treat strokes.

The Robocath R-One cath lab robotic platform being used in Rouen, France, to guide a cardiac Cath procedure. The system gained European approval in 2019. Robocath is now partnering with Philips France and Rennes University Hospital to develop the robotic system to treat strokes.

News | Stroke | July 07, 2021
July 7, 2021 – Robocath, a company that designs, develops and commercializes...
Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.

Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.

News | Stroke | April 07, 2021
April 7, 2021 — Market research firm GlobalData's new report,...
Medical imaging artificial intelligence (AI) vendor Avicenna.AI today announced its FDA-cleared CINA Head triage AI solution will be offered by cloud-based imaging platform Arterys. Supporting the treatment of stroke and neurovascular emergencies, CINA Head detects intracranial hemorrhages (ICHs) and large vessel occlusions (LVOs) from CT-scan imaging. #RSNA20 #RSNA2020

Medical imaging artificial intelligence (AI) vendor Avicenna.AI today announced its FDA-cleared CINA Head triage AI solution will be offered by cloud-based imaging platform Arterys. Supporting the treatment of stroke and neurovascular emergencies, CINA Head detects intracranial hemorrhages (ICHs) and large vessel occlusions (LVOs) from CT-scan imaging.
 

News | Stroke | December 01, 2020
December 1, 2020 – Medical imaging ...
A carotid artery atherosclerotic plaque blockage at the bifurcation seen here can cause strokes. The stenting these lesions is a less invasive way of treating than open vessel surgery. The SVS has issued guidelines to help guide credentialing for the carotid stent procedure. Image from Vital Images.

A carotid artery atherosclerotic plaque blockage at the bifurcation seen here can cause strokes. The stenting these lesions is a less invasive way of treating than open vessel surgery. The SVS has issued guidelines to help guide credentialing for the carotid stent procedure. Image from Vital Images.

News | Stroke | July 09, 2020
July 9, 2020 — The Society for Vascular Surgery (SVS) has release
Synaptive Medical, a leader in robotic surgical visualization, announced today the company has secured approval from Health Canada for Evry, the company’s superconducting, head magnetic resonance imaging (MRI) system
News | Stroke | February 20, 2020
February 20, 2020 — Synaptive Medical, a leader in ro
New Algorithm Expands Neurologists' Ability to Assess for Clot-removing Procedure
News | Stroke | October 18, 2019
An algorithm developed by faculty at The University of Texas Health Science Center at Houston (UTHealth) can help...
Mobile Stroke Unit Gets Patients Quicker Treatment Than Traditional Ambulance

Image courtesy of UTHealth McGovern Medical School

News | Stroke | August 16, 2019
Every second counts for stroke patients, as studies show they can lose up to 27 million brain cells per minute....
MaxQ AI Launches Accipio Ax Slice-Level Intracranial Hemorrhage Detection
Technology | Stroke | May 21, 2019
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that Accipio Ax will begin shipping in August...
Brain images that have been pre-reviewed by the Viz.AI artificial intelligence software to identify a stroke. The software automatically sends and alert to the attending physician's smartphone with links to the imaging for a final human assessment to help speed the time to diagnosis and treatment. Depending on the type of stroke, quick action is needed to either activate the neuro-interventional lab or to administer tPA.

Brain images that have been pre-reviewed by the Viz.AI artificial intelligence software to identify a stroke. The software automatically sends and alert to the attending physician's smartphone with links to the imaging for a final human assessment to help speed the time to diagnosis and treatment. Depending on the type of stroke, quick action is needed to either activate the neuro-interventional lab or to administer tPA. Photo by Dave Fornell.

Feature | Stroke | May 17, 2019 | Inga Shugalo
With its increasing role in medical imaging, ...
Videos | Stroke | May 16, 2019
This is an example of a carotid artery reporting module from Change Healthcare at...